ArticlePloS one2021
Quality assured implementation of the Slovenian breast cancer screening programme.
Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Informing prostate cancer screening policy makers in the European Union: lessons from cancer screening governance and policymaking.European journal of public health · 2025Pooled it
- Why Organised Cancer Screening Works: Lessons from Slovenia and the Next Phase of Evidence-Based Implementation.Zdravstveno varstvo · 2026Article
- Analysis of the effects of individualized nutrition and physical activities on body composition during the treatment of breast cancer patients.Radiology and oncology · 2026Article
- Estimating lead time and overdiagnosis in cancer screening programmes: the MOCCI method.International journal of epidemiology · 2026Article
- Breast cancer in Bosnia and Herzegovina: real-world patterns of diagnosis, treatment, and survival outcomes.Scientific reports · 2026Article
- Evaluation of the Slovenian Breast Cancer Screening Programme: Years of Life Gained and Avoided Deaths.Cancers · 2025Article
- Evaluator's alignment as an important indicator of adequacy of the criteria and assessment procedure for recognizing the good practice in public health.Frontiers in public health · 2024Article
- Breast cancer risk assessment and risk distribution in 3,491 Slovenian women invited for screening at the age of 50; a population-based cross-sectional study.Radiology and oncology · 2023Article
- Prognostic factors and outcomes in women with breast cancer in Slovenia in relation to step-wise implementation of organized screening.PloS one · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
settingThe organised, population-based breast cancer screening programme in Slovenia began providing biennial mammography screening for women aged 50-69 in 2008. The programme has taken a comprehensive approach to quality assurance as recommended by the European guidelines for quality assurance in breast cancer screening and diagnosis (4th edition), including centralized assessment, training and supervision, and proactive monitoring of performance indicators. This report describes the progress of implementation and rollout from 2003 through 2019.
methodsThe screening protocol and key quality assurance procedures initiated during the planning from 2003 and rollout from 2008 of the screening programme, including training of the professional staff, are described. The organisational structure, gradual geographical rollout, and coverage by invitation and examination are presented.
resultsThe nationwide programme was up and running in all screening regions by the end of 2017, at which time the nationwide coverage by invitation and examination had reached 70% and 50%, respectively. Nationwide rollout of the population-based programme was complete by the end of 2019. By this time, coverage by invitation and examination had reached 98% and 76%, respectively. The participation rates consistently exceeded 70% from 2014 to 2019.
conclusionsThe successful implementation of the screening programme can be attributed to an independent central management, external guidance, and strict adherence to quality assurance procedures, all of which contributed to increasing governmental and popular support. The benefits of quality assurance have influenced all aspects of breast care and have provided a successful model for multidisciplinary management of other diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.